Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NBIX 
Neurocrine Biosciences Inc (NBIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: NBIX (1-star) is a SELL. SELL since 2 days. Simulated Profits (1.19%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $169.48
1 Year Target Price $169.48
| 15 | Strong Buy |
| 7 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.94% | Avg. Invested days 39 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.55B USD | Price to earnings Ratio 40.42 | 1Y Target Price 169.48 |
Price to earnings Ratio 40.42 | 1Y Target Price 169.48 | ||
Volume (30-day avg) 25 | Beta 0.21 | 52 Weeks Range 84.23 - 154.61 | Updated Date 10/12/2025 |
52 Weeks Range 84.23 - 154.61 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.88% | Operating Margin (TTM) 21.18% |
Management Effectiveness
Return on Assets (TTM) 8.67% | Return on Equity (TTM) 13.39% |
Valuation
Trailing PE 40.42 | Forward PE 25.77 | Enterprise Value 13025579677 | Price to Sales(TTM) 5.4 |
Enterprise Value 13025579677 | Price to Sales(TTM) 5.4 | ||
Enterprise Value to Revenue 5.19 | Enterprise Value to EBITDA 23.38 | Shares Outstanding 99181510 | Shares Floating 98005217 |
Shares Outstanding 99181510 | Shares Floating 98005217 | ||
Percent Insiders 1.05 | Percent Institutions 101.88 |
Upturn AI SWOT
Neurocrine Biosciences Inc
Company Overview
History and Background
Neurocrine Biosciences Inc. was founded in 1992. Initially focused on gene therapy, it transitioned to developing treatments for neurological and endocrine-related disorders. A significant milestone was the approval of INGREZZA for tardive dyskinesia in 2017, marking its first commercial product. The company has since expanded its pipeline and commercial capabilities.
Core Business Areas
- Neurology: Develops and commercializes treatments for neurological disorders, focusing on movement disorders such as tardive dyskinesia (TD) and Parkinson's disease.
- Endocrinology: Develops and commercializes treatments for endocrine-related disorders, targeting conditions such as congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
Leadership and Structure
Kevin Gorman serves as the CEO. The organizational structure is based on functional departments (R&D, Commercial, Finance, etc.) with a focus on therapeutic areas.
Top Products and Market Share
Key Offerings
- INGREZZA (valbenazine): INGREZZA is a VMAT2 inhibitor used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease. It has a significant market share in the TD treatment market. Competitors include Teva Pharmaceutical's Austedo and generic options.
- ORILISSA (elagolix): ORILISSA is a GnRH antagonist used for managing moderate to severe endometriosis-associated pain and uterine fibroids. Marketed in collaboration with AbbVie. Competitors include generics for uterine fibroids and hormonal birth control pills for endometriosis.
- CRINE CERVI (gonadorelin): CRINE CERVI is a synthetic gonadotropin-releasing hormone indicated for the treatment of delayed puberty caused by low levels of a certain hormone. Competitors include generics with different drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and patent protection. The neurology and endocrinology segments are experiencing growth due to aging populations and increasing prevalence of chronic diseases.
Positioning
Neurocrine Biosciences is positioned as a specialty pharmaceutical company focused on neurological and endocrine disorders. Its competitive advantages include its expertise in VMAT2 inhibition, strong commercial capabilities, and a robust pipeline.
Total Addressable Market (TAM)
The TAM for Neurocrine's key indications (TD, endometriosis, CAH) is estimated at several billion dollars. Neurocrine is positioned to capture a significant portion of this market through its established products and pipeline.
Upturn SWOT Analysis
Strengths
- Successful commercialization of INGREZZA
- Strong expertise in neurology and endocrinology
- Robust pipeline of drug candidates
- Strategic partnerships with companies like AbbVie
- Consistent revenue growth
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Vulnerability to patent expirations
- Competition from larger pharmaceutical companies
- Regulatory risks
Opportunities
- Expansion into new indications within neurology and endocrinology
- Acquisition of promising drug candidates
- Strategic collaborations to expand market reach
- Growing prevalence of neurological and endocrine disorders
- Advancements in drug delivery technologies
Threats
- Generic competition
- Regulatory setbacks
- Clinical trial failures
- Pricing pressures
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- ABBV
- Lilly
Competitive Landscape
Neurocrine Biosciences has a competitive advantage in the TD market with INGREZZA. However, it faces competition from larger pharmaceutical companies in other therapeutic areas. Its pipeline and strategic partnerships are key to maintaining its competitive position.
Major Acquisitions
Idorsia Pharmaceuticals U.S. Inc
- Year: 2024
- Acquisition Price (USD millions): 53
- Strategic Rationale: Acquired exclusive global rights to NBI-82714, a novel molecule to treat a rare form of epilepsy.
Growth Trajectory and Initiatives
Historical Growth: Neurocrine has experienced significant revenue growth driven by INGREZZA sales. The company has also expanded its pipeline through internal development and acquisitions.
Future Projections: Analyst estimates suggest continued revenue growth driven by INGREZZA and pipeline advancements. The company's focus on neurological and endocrine disorders positions it for long-term growth.
Recent Initiatives: Recent initiatives include expanding the label for INGREZZA, advancing clinical trials for CAH, and pursuing strategic collaborations.
Summary
Neurocrine Biosciences is a strong company with a successful commercial product, INGREZZA, driving revenue growth. The company's focus on neurology and endocrinology, along with its pipeline and strategic partnerships, positions it for continued growth. However, it faces competition from larger pharmaceutical companies and regulatory risks, and R&D setbacks. Neurocrine Biosciences needs to continue growing in other related sectors to drive revenues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neurocrine Biosciences Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.neurocrine.com |
Full time employees 1800 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.